Introduction
Treatment for acute myeloid leukemia can involve intensive chemotherapy followed by continued treatment designed to help maintain remission. For some adults who achieve a first remission after intensive induction chemotherapy but cannot complete intensive curative therapy, Onureg provides an oral continuation-treatment option.
Onureg contains azacitidine, a nucleoside metabolic inhibitor that affects processes involved in DNA and RNA function and gene regulation. By interfering with abnormal gene regulation and leukemia-cell growth, it is used to help maintain control of AML after initial intensive chemotherapy.
Although this medication and injectable azacitidine contain the same active ingredient, they are different formulations with different approved uses and dosing schedules. Onureg should not be substituted for intravenous or subcutaneous azacitidine.
As a specialty cancer medication, this medication can be expensive. Actual patient costs may vary considerably depending on insurance coverage, pharmacy benefits, formulary status, quantity dispensed, and available financial assistance.
Prescription Hope provides medication assistance support for eligible patients seeking more affordable access to prescription medications. Understanding available patient assistance options can be an important part of navigating the financial side of ongoing AML treatment.
What Is the Onureg Patient Assistance Program?
Understanding Onureg Prescription Assistance
Patients often search for Onureg patient assistance programs or Onureg medication access programs due to the high cost of their specialty medication.
Many manufacturers offer patient assistance programs to help qualified patients afford their brand-name medications.
Unfortunately, these programs have been known to be difficult to navigate, leaving patients frustrated when applying on their own.
How Expert Advocates Help Make Onureg More Affordable
Personalized Medication Assistance
Patients looking for trusted prescription assistance specialists and azacitidine assistance can find those specialists at Prescription Hope. Our patient support services take care of the application process for patient assistance programs, from start to finish.
Our dedicated team manages form completion, document and signature collection, coordination with healthcare providers and manufacturers, and all the minutiae that come with patient assistance programs like those for specialty oncology medication assistance.
Ongoing Patient Support
We also offer long-term medication assistance. Onureg patient support through Prescription Hope simplifies the application process for you through our thorough approach. Our team manages tedious administrative tasks such as form and document updates, issue resolution, program monitoring, yearly renewals, and even refill scheduling.
Onureg Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Navigating Treatment Costs
While AML treatment costs can be extremely expensive, Onureg cost assistance through Prescription Hope can make all the difference.
For $70.00 per month, per medication, qualified patients get access to affordable AML treatment cost assistance without any hidden charges or fees, variable pricing systems, or medication costs.
Onureg Patient Assistance Eligibility
General Eligibility Requirements
While determining specific Onureg patient assistance eligibility is best done by enrolling with Prescription Hope, it is also helpful to understand the general patient assistance program requirements.
They include:
Income: Each program maintains its own income threshold.
Insurance: Each program maintains its own requirement regarding insurance coverage status.
Prescription: All qualified patients must have a valid prescription for the name-brand medication that they wish to apply for.
U.S. Residency: All qualified patients must have legal U.S. residency.
Simple Enrollment With Expert Support
Getting Started With Enrollment
Do you need prescription assistance application help? Enroll with Prescription Hope today. Medication assistance enrollment only takes 6 simple steps:
- Submit Information: Our online form can be completed in a few minutes from the comfort of your own home.
- Document Collection: Following a quick prequalification, our team will collect the needed documents.
- Provider Coordination: Our team connects with your healthcare provider to secure vital signatures.
- Program Submission: Our team completes your application packet, submits it, and continues to follow up with the manufacturer.
- Medication Delivery: Once approved, qualified patients can typically expect to receive their medication within two weeks, though shipping times may vary. All medication shipments arrive directly from the manufacturer to your home or doctor’s office.
Understanding Onureg
How Onureg Works
Onureg contains azacitidine, a nucleoside metabolic inhibitor and hypomethylating agent that affects processes involved in DNA and RNA function and gene regulation.
Azacitidine inhibits DNA methyltransferases and becomes incorporated into DNA and RNA. These actions can alter abnormal gene activity and interfere with the growth and survival of cancer cells.
In simple terms, this medication helps disrupt abnormal gene regulation and leukemia-cell growth. This activity supports its use as continued treatment after intensive chemotherapy has already achieved a first remission in appropriately selected adults with AML.
The relationship between azacitidine’s molecular effects and its clinical antileukemic activity is complex and has not been completely established.
An important distinction is that this medication is an oral formulation of azacitidine with its own approved indication and dosing schedule. It must not be substituted for intravenous or subcutaneous azacitidine, even though those products contain the same active ingredient.
What Conditions Does Onureg Treat?
Onureg is FDA-approved for the continued treatment of adults with acute myeloid leukemia (AML) who have achieved a first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are unable to complete intensive curative therapy.
This medication is used as continued or maintenance treatment following the initial intensive chemotherapy. The goal is to help maintain remission and delay recurrence of AML.
It is not approved as initial induction therapy for newly diagnosed AML. It should also not be presented as interchangeable with injectable azacitidine products.
It is not FDA-approved for myelodysplastic syndromes (MDS). The FDA prescribing information specifically states that treatment of patients with MDS using Onureg is not recommended outside controlled clinical trials. This distinction is important because injectable azacitidine is used to treat certain MDS patients, but that does not make this medication an FDA-approved MDS treatment.
Safety and effectiveness of Onureg have not been established in pediatric patients.
Benefits of Treatment
For appropriately selected adults with AML who have achieved a first remission following intensive induction chemotherapy, Onureg provides an oral continuation-treatment option when intensive curative therapy cannot be completed.
In the clinical trial supporting FDA approval, continued treatment improved overall survival compared with placebo in the studied population. Treatment may help maintain remission and delay AML recurrence.
This medication is taken at home as an oral medication rather than being administered as an infusion or injection. The recommended regimen consists of 300 mg once daily on Days 1 through 14 of each 28-day cycle, with treatment continuing until disease progression or unacceptable toxicity.
It is intended to continue treatment after remission has been achieved. It does not replace the intensive induction chemotherapy used to achieve remission.
Individual treatment responses vary, and the healthcare team determines whether Onureg remains appropriate based on disease status, treatment response, side effects, and other clinical considerations.
Important Safety Information and Side Effects
Onureg does not carry an FDA Boxed Warning. However, the prescribing information includes important warnings and precautions involving myelosuppression, serious infections, gastrointestinal toxicity, embryo-fetal toxicity, and the risk associated with using Onureg for MDS outside controlled clinical trials.
Important Formulation Warning
Although Onureg and injectable azacitidine contain the same active ingredient, they are not interchangeable.
Onureg has different pharmacokinetic properties, dosing, and approved uses from intravenous and subcutaneous azacitidine. Patients should not substitute one formulation for another unless specifically directed by their healthcare provider.
Myelosuppression
Onureg can cause significant bone marrow suppression, including neutropenia, thrombocytopenia, anemia, and febrile neutropenia.
The FDA recommends monitoring complete blood counts every other week during the first two treatment cycles and before the beginning of each subsequent treatment cycle. Additional every-other-week monitoring is recommended for two cycles following a dose reduction.
Depending on the severity of the blood-count abnormality, treatment may need to be withheld, resumed at a reduced dose, or discontinued.
Serious Infections
Myelosuppression associated with this medication can increase susceptibility to serious infections, including pneumonia, sepsis, and bacterial, viral, and fungal infections.
Patients should promptly contact their healthcare provider if they develop fever or other symptoms that could indicate an infection.
Gastrointestinal Toxicity
Nausea, vomiting, and diarrhea are common with Onureg and can sometimes be severe.
An antiemetic should be administered approximately 30 minutes before each Onureg dose during at least the first two treatment cycles.
If a patient does not experience nausea or vomiting after two treatment cycles, the healthcare provider may determine that prophylactic antiemetic treatment can be omitted.
MDS Warning
Onureg is not FDA approved for myelodysplastic syndromes.
The FDA prescribing information states that treatment of patients with MDS using Onureg is not recommended outside controlled clinical trials. This recommendation is based on an earlier clinical study in which this medication was associated with a higher incidence of early fatal and serious adverse reactions, including sepsis, compared with placebo.
This warning should not be confused with the use of injectable azacitidine in MDS. Injectable azacitidine and Onureg are different formulations with different indications and dosing regimens.
Embryo-Fetal Toxicity
Onureg can cause fetal harm because of azacitidine’s mechanism of action and findings from animal studies.
Pregnancy testing should be performed before treatment in females of reproductive potential. Patients should discuss reproductive risks and appropriate contraception with their healthcare provider before beginning treatment.
Pregnancy
This medication can cause fetal harm.
The FDA recommends effective contraception during treatment and for at least 6 months after the final dose for females of reproductive potential.
For males with female partners of reproductive potential, effective contraception is recommended during treatment and for at least 3 months after the final dose.
Patients should contact their healthcare provider if pregnancy occurs during treatment.
Animal studies demonstrated fetal death and developmental abnormalities at exposures below the recommended human dose.
Breastfeeding
There are no available data regarding the presence of azacitidine in human milk, its effects on a breastfed infant, or its effects on milk production.
Because of the potential for serious adverse reactions in a breastfed child, patients should not breastfeed during treatment with Onureg and for 1 week after the final dose.
Common Side Effects
The current FDA labeling identifies several adverse reactions occurring in at least 10% of patients.
These include nausea, vomiting, diarrhea, fatigue or asthenia, constipation, upper respiratory tract infection, pneumonia, abdominal pain, arthralgia, decreased appetite, febrile neutropenia, dizziness, skin infection, and pain in an extremity.
The most clinically important concerns include myelosuppression, gastrointestinal toxicity, and infections. Patients should discuss new or worsening symptoms with their healthcare provider during treatment.
Contraindication
Onureg is contraindicated in patients with a history of severe hypersensitivity to azacitidine or any component of Onureg.
Patients should provide their healthcare provider with information about previous allergic reactions and all medications and supplements they use before starting treatment.
Access to Multiple Medications
Support Beyond Onureg
Do you need AML medication assistance as well as other specialty medication access?
Prescription Hope medication assistance routinely helps qualified patients access multiple medication assistance programs at once. Whether one or many, our dedicated team provides all services for a simple $70.00 per month, per medication.
Why Choose Prescription Hope for Onureg Assistance
Patient-Focused Medication Support
For two decades, the dedicated patient advocate team at Prescription Hope has helped qualified patients receive patient-focused medication assistance and support that provides them with affordable medication access. Our Florida- based medication access specialists can provide [prescription name] assistance through Prescription Hope.
Simplified Access to Specialty Therapies
At Prescription Hope, our AML medication access and prescription assistance help provide qualified patients with the support they need to access azacitidine medication assistance, lower their medication costs, and have peace of mind when it comes to prescription medication prices.
Ongoing Prescription Assistance
Not only does Prescription Hope provide medication affordability support, but we also provide ongoing medication assistance. Our dedicated team of patient advocates takes care of form and document updates, issue resolution, yearly renewals, program monitoring, and even scheduling refills.
Are you looking for Onureg financial support and/or access to affordable brand-name medications like Onureg? Be sure to enroll with Prescription Hope today!